Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML


Allogeneic stem cell transplantation represents the most active form of anti-leukaemic therapy in acute myeloid leukaemia (AML). Advances in transplant technology and supportive care have resulted in improved outcomes in patients allografted using a myeloablative conditioning regimen. At the same time the use of reduced-intensity conditioning regimens has allowed an immunologically mediated graft-versus-leukaemia effect to be exploited in older patients who were previously ineligible for transplantation on the grounds of age or comorbidity. This coupled with the increased availability of alternative stem cell sources, in the form of either unrelated or cord blood donations, has established allogeneic transplantation as a key therapeutic strategy in the treatment of both younger and older adults with AML.

DOI: 10.1038/sj.bmt.1705975
Citations per Year

438 Citations

Semantic Scholar estimates that this publication has 438 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Craddock2008FullintensityAR, title={Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML}, author={Charles Craddock}, journal={Bone Marrow Transplantation}, year={2008}, volume={41}, pages={415-423} }